FDA-approved1,2Evidence: Large human trialsInfections

Dalbavancin1

Also called Dalvance1,2

Key takeaway

Dalbavancin is a lipoglycopeptide antibiotic, a member of the glycopeptide family, and the active ingredient in Dalvance.1,2 FDA approved Dalvance in 2014 for acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).1,2 Two randomized, double-blind trials in 1,312 adults compared it with vancomycin. The label has no boxed warning but warns of serious allergic reactions.1

Dalbavancin at a glance

What it isA lipoglycopeptide antibacterial made from a fermentation product of Nonomuraea bacteria, consisting of five closely related active forms, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Dalvance, NDA 021883, with an original approval date of May 23, 2014. The label has no boxed warning.1,2
Human evidenceTwo phase 3 randomized, double-blind trials in 1,312 adults with skin infections, and a third comparing two treatment plans, described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is dalbavancin?

Dalbavancin is a lipoglycopeptide antibacterial synthesized from a fermentation product of Nonomuraea bacteria. The label states that it is a mixture of five closely related active forms that share a core structure and differ in a fatty-acid side chain.1

In the United States it is the active ingredient of Dalvance, approved under NDA 021883, according to Drugs@FDA.2

How does dalbavancin work?

It is an antibacterial drug active against Gram-positive bacteria such as Staphylococcus aureus, including methicillin-resistant strains, and several streptococci, according to the label.1

The label states that its antibacterial activity in animal infection models correlates best with the ratio of drug exposure over time to the minimum concentration that inhibits the bacteria.1

What do human studies show?

Trials 1 and 2 randomly assigned 1,312 adults with acute bacterial skin infections, such as cellulitis, major abscesses and wound infections, to dalbavancin or vancomycin, with an option to switch to linezolid, according to the label.1

Clinical success at day 26 to 30 was 83.7% with dalbavancin and 88.1% with the comparator in Trial 1, and 88.1% and 84.5% in Trial 2, in the intent-to-treat population. A third trial in 698 patients compared two treatment plans of dalbavancin with similar results.1

What the evidence base contains

  • Large randomized human trial Trials 1 and 2: phase 3 randomized, double-blind, double-dummy trials in 1,312 adults with acute bacterial skin and skin structure infections, comparing dalbavancin with vancomycin (with an option to switch to linezolid), described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is dalbavancin FDA-approved?

Yes. Drugs@FDA lists Dalvance, NDA 021883, with an original approval date of May 23, 2014.2

The Dalvance label cited here (DailyMed SPL version 29, published November 17, 2025) states that it is indicated for adult and pediatric patients with acute bacterial skin and skin structure infections caused by designated susceptible Gram-positive bacteria.1

The label has no boxed warning. It warns of serious allergic and skin reactions, reactions during rapid infusion and raised liver enzymes, and advises care in people allergic to other glycopeptides.1

Timeline

  1. FDA approves Dalvance, NDA 021883, according to Drugs@FDA.2
  2. DailyMed publishes version 29 of the Dalvance label, the version cited here.1

What is still unknown?

Its effectiveness for infections outside the skin, which its approved indication does not cover.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Dalbavancin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Dalbavancin are a bounded selection, not every registration or paper about Dalbavancin. For the years before Dalbavancin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Dalbavancin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Dalbavancin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Dalvance for acute bacterial skin infections. Approval rests on two randomized, double-blind trials in 1,312 adults comparing it with vancomycin. The label has no boxed warning.↗↗

Status sources checked through November 16, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Dalbavancin?

FDA-approved as Dalvance for acute bacterial skin infections. Approval rests on two randomized, double-blind trials in 1,312 adults comparing it with vancomycin. The label has no boxed warning.↗↗

The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
12
Drugs@FDA applications
6

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Dalbavancin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

46Selected dated records
48Connected citations
12Populated source years2009–2026
3/4Record lanes present

Registered human studies

Trial composition

10 of 11 selected trial records include at least one phase value; 11 of 11 include a status value in the retained structured contract.

PhasesPhase 1 3Phase 3 3Phase 4 2Not applicable 1Phase 2 1
Status at observationCompleted 9Active, not recruiting 1Recruiting 1

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 24Review 20Research Support, Non-U.S. Gov't 3Systematic Review 3Clinical Trial 1Clinical Trial, Phase II 1Clinical Trial, Phase III 1Comparative Study 1Letter 1Meta-Analysis 1Randomized Controlled Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
6
FDA Federal Register documents
4
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
46

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 46 dated records

Research hub

Explore the Dalbavancin evidence record

Open all 46 records →
46Dated records
3Evidence types
46Cited public sources
12Source years

Change ledger

Recently changed for Dalbavancin

Open all 46 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Official-source collections

Source records for Dalbavancin

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026 03 01
  2. [Translated article] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections.Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 2025 09 23
  3. Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients.Antibiotics (Basel, Switzerland) · 2025 01 23
Explore all selected literature →
ClinicalTrials.gov11

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06810583Registry update September 15, 2026 · current at observation
  2. NCT05046860Registry update June 22, 2026 · current at observation
  3. NCT02814916Registry update September 19, 2024 · completed at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA6

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA219604Full FDA chronology · original submission status AP 2026-06-04
  2. ANDA218602Full FDA chronology · original submission status AP 2026-02-26
  3. ANDA218929Full FDA chronology · original submission status AP 2025-11-26
  4. ANDA217591Full FDA chronology · original submission status AP 2025-11-10
  5. ANDA219465Full FDA chronology · original submission status AP 2025-10-23
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Dalbavancin →

Evidence types

Coverage by source year

Selected records span October 12, 2009 to October 10, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2
Dated updates connected to this profile · 46

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.↗

    PubMed lists PMID 34931283 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2021-12-21 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT06810583↗

    PeptideScanner retained ClinicalTrials.gov record NCT06810583 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

  3. Literature metadata

    Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.↗

    PubMed lists PMID 41892415 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-03-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Federal Register notice 2026-15149↗

    The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT05046860↗

    PeptideScanner retained ClinicalTrials.gov record NCT05046860 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-06-22, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

  6. Regulatory

    Drugs@FDA application ANDA219604↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.↗

  7. Literature metadata

    [Translated article] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections.↗

    PubMed lists PMID 40993014 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Systematic Review, Journal Article, with publication-date metadata of 2025-09-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Regulatory

    Drugs@FDA application ANDA218602↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗

  9. Literature metadata

    Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.↗

    PubMed lists PMID 32603683 in International journal of antimicrobial agents as Journal Article, Systematic Review, with publication-date metadata of 2020-06-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review.↗

    PubMed lists PMID 32629114 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-03 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    The current and future off-label uses of dalbavancin: a narrative review.↗

    PubMed lists PMID 36808371 in European review for medical and pharmacological sciences as Review, Journal Article, with publication-date metadata of 2023-02 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Regulatory

    Drugs@FDA application ANDA218929↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    DALVANCE (dalbavancin) for injection · SPL version 29 · published 2025-11-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: DALVANCE (dalbavancin hydrochloride), NDA 021883 · original approval May 23, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026